Brind.

Analyst questions were raised on August 13, 2025, regarding the sustainability of Xywav patient adds for Jazz Pharmaceuticals.

1 report, 1 independent Updated Aug 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Jazz Pharmaceuticals Bank of America

Keep exploring

The entities involved

Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
- Jazz Pharmaceuticals plans U.S. launch of Ziihera.Wed 22:28
- Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.Wed 13:55
Bank of America
American multinational banking and financial services corporation
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
- Both Bank of America and Deloitte have addressed current treasury management trends.Mon 14:26

Coverage

Newest first; wire copies grouped

Aug 13StockStoryThe 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call Jazz Pharmaceuticals’ second quarter saw management attribute performance to solid momentum in its neuroscience p